The Quantellect read.As of Nov 19, 2026, 8 active firms cover Gossamer Bio Inc: 5 rate it Buy or better, 2 sit at Neutral, and 1 rate it Sell or worse, a neutral consensus. The target range is very wide, $0.28 to $160.00 (about 571.4x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $37.04 sits 224% above the current $11.42. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-4.77 next quarter toward $-12.16 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 active firms
Neutral
Strong Buy00%
Buy563%
Neutral225%
Sell113%
Strong Sell00%
Based on 8 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$37.04
+224.3% upside
Average target across 7 active firms as of Nov 19, 2026 vs $11.42 current
Highest Target$160.00
Average Target$37.04
Lowest Target$0.28
Detailed analyst forecasts for GOSS
Showing 1–7 of 7 named analysts shown · 8 active firms in the rating projection
As of Nov 19, 2026, 5 of 8 active firms rate GOSS a Buy (2 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
GOSS EPS & revenue forecast
EPS · NEXT QUARTER
$-4.77
Range $-5.60 – $-3.20 · 4 analysts · -72% YoY
Next period, 4 analysts expect Gossamer Bio Inc to earn $-4.77 a share (range $-5.60 – $-3.20), versus $-16.80 a year earlier. Full-year consensus is $-18.88, growing to $-12.16 the year after.
REVENUE · NEXT QUARTER
$700.0K
Range $0 – $4.2M · 4 analysts · -96% YoY
Revenue is expected to reach $700.0K (range $0 – $4.2M), -95.9% year-over-year. Full-year consensus is $64.6M, rising to $18.0M next year.
Top analysts covering Gossamer Bio Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on GOSS.
#1
Laura Chico
Wedbush · Rank #55
Neutral
$1.00-91.2% to target
Overall win rate
46%
+ Follow
#2
Paul Choi
Goldman Sachs · Rank #110
Neutral
$40.00+250.3% to target
Overall win rate
52%
+ Follow
#3
Greg Harrison
Scotiabank · Rank #223
Buy
$11.00-3.7% to target
Overall win rate
38%
+ Follow
#4
Joseph Schwartz
Leerink Partners · Rank #242
Buy
$1.00-91.2% to target
Overall win rate
36%
+ Follow
#5
Patrick R. Trucchio
HC Wainwright & Co. · Rank #308
Buy
$90.00+688.1% to target
Overall win rate
36%
+ Follow
GOSS stock forecast FAQ
What is GOSS's average 12-month price target?+
The 7 active firms with a live target average $37.04 for Gossamer Bio Inc over the next 12 months, ranging from a $160.00 high to a $0.28 low, as of Nov 19, 2026.
Is GOSS stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 8 active firms as of Nov 19, 2026, 5 rate it Buy or Strong Buy, 2 rate it Neutral, and 1 rate it Sell or Strong Sell.
What are the highest and lowest price targets for GOSS?+
The Street-high target is $160.00 (Chardan Capital), and the Street-low is $0.28 (Barclays). The average of all 7 active-firm targets is $37.04.
How many active Wall Street firms cover GOSS?+
8 active firms have a recognized rating on Gossamer Bio Inc as of Nov 19, 2026, and 7 active firms carry a live 12-month price target.
Who is the most accurate analyst covering GOSS?+
Among analysts who currently cover GOSS, Laura Chico of Wedbush has the strongest overall Quantellect track record (Rank #55). Their current call is Neutral with a $1.00 target.
What is Gossamer Bio Inc's projected EPS for next quarter?+
The consensus estimate is $-4.77 per share (range $-5.60 – $-3.20) across 4 analysts. Full-year EPS is projected at $-18.88, rising to $-12.16 the following year.
How much revenue is Gossamer Bio Inc expected to report next quarter?+
Consensus revenue is $700.0K (range $0 – $4.2M). Full-year revenue is projected at $64.6M, growing to $18.0M next year.
Have analysts been upgrading or downgrading GOSS lately?+
As of Nov 19, 2026, 5 of 8 active firms rate GOSS a Buy (2 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their GOSS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.